SEED Therapeutics to Present Phase 1 ST-01156 Design at ASCO 2026
Key Takeaways
- ST-01156 is being presented at ASCO 2026 as a first-in-human Phase 1 program in the RBM39 molecular glue degrader class.
- The ongoing study enrolls patients with advanced solid malignancies, focusing on RBM39-dependent cancers, to characterize safety, pharmacology, and early signals of activity.
- The release also provides conference logistics, including the poster topic, session, timing, location, and abstract and poster identifiers.
SEED said the poster will outline the ongoing Phase 1 study and the preclinical rationale for advancing ST-01156 into human testing. The study includes patients with advanced solid malignancies, with an emphasis on RBM39-dependent cancers. Eligible patients have exhausted standard treatment options. SEED also describes RBM39 as an oncology target whose therapeutic potential has been limited by prior chemical matter.
The study is structured to characterize safety, pharmacology, and early signals of activity in this patient group. SEED also describes ST-01156 as orally administered, selective, and brain-penetrant, but these features are presented as program attributes rather than demonstrated clinical advantages. The release further states that the candidate was designed with the pharmacologic profile required for patients with advanced solid tumors.
The ASCO Annual Meeting is scheduled for May 29 through June 2 in Chicago, and the release lists a poster title on first-in-human evaluation of ST-01156. Eric K. Rowinsky, SEED's clinical and medical lead, is identified as presenting author, and the company lists additional coauthors in the abstract record. The session is Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology. The poster presentation details place it on Saturday, May 30, from 1:30 p.m. to 4:30 p.m. CDT.